We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the FDA revisits its decision to remove it.

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

branded as Zepbound. Writing for the U.K.’s The Telegraph newspaper, Secretary of State for Health & Social Care Wes Streeting announced the five-year real-world study on Monday. It aims to ...

The Food and Drug Administration (FDA) recently removed Eli Lily's weight-loss drug from its shortage list, which some industry officials and medical experts argue will complicate access for some ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...